4-(Methylsulfonyl) Acidum phenylaceticum CAS 90536-66-6 Puritas >99.5% (HPLC)
Ducens Fabrica et Supplier, Intermedia de Etoricoxib
Etoricoxib API CAS 202409-33-4
4-(Methylthio) Acidum Phenylaceticum CAS 16188-55-9
4-(Methylsulfonyl) Acidum Phenylaceticum CAS 90536-66-6
Please contact: alvin@ruifuchem.com
Nomen chemicum | 4-(Methylsulfonyl) phenylaceticum acidum |
Synonyma | 4-Methylsulphonylphenylacetic Acid;4-(Methanesulfonyl) phenylaceticum Acidum;(4-Methanesulfonylphenyl) acetic Acidum;4-Methylsulfonyl Phenyl Acidum aceticum;2-(4-(Methylsulfonyl)phenyl)acetic Acidum;[p-(Methylsulfonyl)phenyl]4-Mesylphenylacetic Acid |
CAS Number | 90536-66-6 |
CATTUS Number | RF-PI1182 |
Stock Status | In Stock, Productio Ascendite ad Tons |
Formulae hypotheticae | C9H10O4S |
M. Pondus | 214.24 |
Liquescens punctum | 136.0 ad 140.0℃ |
Density | 1.35 |
Solubilitas | Solutum in Methanol |
Brand | Ruifu Chemical |
Item | Specifications |
Aspectus | White ad Off-White solidus pulveris |
Puritas / Analysis Methodus | >99.5% (HPLC) |
Liquescens punctum | 136.0 ad 140.0℃ |
Humor (KF) | <0.50% |
Uno maxima immunditia | <0.30% |
Totalis immunditias | <0.50% |
Infrared Imaginis | Conformat ut Structure |
Test Standard | Enterprise Standard |
Consuetudinem | Medium Etoricoxib (CAS: 202409-33-4) |
sarcina: Utrem, aluminium foil, sacculum, 25kg/cardboard Drum, vel secundum exigentiam emptoris
Repono Condition:Repone in vasis signatis in loco frigido et sicco;Protege a lumine et humore
![1](https://a395.goodao.net/uploads/15.jpg)
![www.ruifuchem.com](https://a395.goodao.net/uploads/Pregabalin-CAS-148553-50-8-Factory-Shanghai-Ruifu-Chemical-Co.-Ltd.-www.ruifuchemical.com_.png)
4-(Methylsulfonyl) Acid phenylaceticum (CAS: 90536-66-6) medium est ex Etoricoxib (CAS: 202409-33-4).Etoricoxib genus est cyclooxygenase-selectivum valde 2 (COX-2) inhibitoribus a comitatu Merck elaboratum.Etoricoxib late in curatione OSTEOARTHRITIS (OA), arthritis rheumatoideis, spondylitis ankylosing, longis retro dolor, podagris acutis, arthritis primariis dysmenorrhea et postoperative, aliisque morbis.Etoricoxib, COX-2 inhibitor selectivus, effectus habet anti-inflammatores, analgesicos et antipyreticos, aptus curationi symptomatum et signa osteoarthritis acutis et longis, item arthritis acutis podagrae.Celeriter Etoricoxib absorbetur, cum bioavailability oralis 80 ad 100%, et maximam plasma concentrationis in 1 ad 2 horas post dosing pervenit.Cibus minuit effusio ratem, sed in quantum effusio non valet.Exhibet longam eliminationem vitae dimidiae circiter 22 horarum, demonstrans plasma pharmacokineticorum linearium sine cumulatione in multiplici dosing.